Stocks Health care COLL
NASDAQ · Health careCollegium Pharmaceutical, Inc (COLL)
Collegium Pharmaceutical, Inc brought in $815.2M of revenue over the twelve months to September 30, 2026, up 7.7% from a year earlier. Net income was $38.2M, a net margin of 4.7%. Operating cash flow minus capital spending left $327.6M of free cash flow in fiscal 2025. At September 30, 2026 it held $144.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Collegium Pharmaceutical, Inc
- Net worth
- Collegium Pharmaceutical, Inc has a market value (market cap) of $796.6M at the latest share price, and shareholders' equity of $296.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $780.6M (+23.6% year on year), with net income of $62.9M. Over the 12 months to September 30, 2026: revenue $815.2M, net income $38.2M.
- Cash flow
- In fiscal 2025 operations brought in $329.3M of cash; after $1.7M of capital spending, free cash flow was $327.6M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Collegium Pharmaceutical, Inc's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Collegium Pharmaceutical, Inc does
Collegium Pharmaceutical, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker COLL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $780.6M | $62.9M | $1.73 | $327.6M |
| 2024 | $631.4M | $69.2M | $1.86 | $203.3M |
| 2023 | $566.8M | $48.2M | $1.29 | $274.3M |
| 2022 | $463.9M | -$25M | -$0.74 | $122.6M |
| 2021 | $276.9M | $71.5M | $1.86 | $101.6M |
| 2020 | $310M | $26.8M | $0.76 | $88.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where COLL ranks in Health care
Latest SEC filings
What Collegium Pharmaceutical, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 3.3% to $216.3M versus the same quarter last year; diluted EPS $0.60 versus $0.84.
- November 5, 2026
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 29, 2026Passive stake changed SCHEDULE 13G/A
- October 19, 2026
- October 8, 2026Passive stake changed SCHEDULE 13G/A
- August 24, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Other event 8-K
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 6.3% to $199.9M versus the same quarter last year; diluted EPS -$0.46 versus $0.34.
What is COLL worth? A DCF from its reported cash flow
Insider trades
What the people running Collegium Pharmaceutical, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 8, 2026 | Santini GinoDirector | Exercised options | 8,700 | $143.5K |
| May 18, 2026 | Freund John GordonDirector | Sold | 20 | $681 |
| May 15, 2026 | Freund John GordonDirector | Exercised options | 8,700 | $143.5K |
| May 15, 2026 | Freund John GordonDirector | Sold | 4,127 | $142.5K |
| May 14, 2026 | Bohlin Garen GDirector | Received as pay | 8,741 | - |
| May 14, 2026 | Santini GinoDirector | Received as pay | 8,741 | - |
| May 14, 2026 | Freund John GordonDirector | Received as pay | 8,741 | - |
| May 14, 2026 | Lurker NancyDirector | Received as pay | 8,741 | - |
Who owns COLL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Millennium Management LLC13G, passive with 3 related filers | 7.4% | October 8, 2026 |
| Janus Henderson Group PLC13G, passive | 5.8% | May 15, 2026 |
| Fuller & Thaler Asset Management, Inc.13G, passive | 5.03% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.01% | July 31, 2026 |
| Principal Global Investors13G, passive | 5% | August 5, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 279 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,441,202 | +307,175 |
| Jupiter Topco LLC | 2,147,072 | new |
| Invesco Ltd. | 1,882,499 | +290,590 |
| Fuller & Thaler Asset Management, Inc. | 1,632,781 | +133,197 |
| Principal Financial Group Inc | 1,632,360 | +337,332 |
| State Street Corp | 1,528,881 | +104,337 |
| Massachusetts Financial Services Co | 1,405,567 | +39,635 |
| Vanguard Capital Management LLC | 1,381,261 | +47,269 |
| Renaissance Technologies LLC | 1,366,549 | -102,900 |
| Eventide Asset Management, LLC | 1,361,228 | -63,054 |
| Rubric Capital Management LP | 1,279,611 | 0 |
| Geode Capital Management, LLC | 890,886 | +71,446 |
| Dimensional Fund Advisors LP | 837,877 | +4,685 |
| Victory Capital Management Inc | 760,252 | +134,948 |
| Goldentree Asset Management LP | 744,889 | new |
| Vanguard Portfolio Management LLC | 740,081 | +59,700 |
| Millennium Management LLC | 736,925 | +376,099 |
| Arrowstreet Capital, Limited Partnership | 621,920 | -81,608 |
| Assenagon Asset Management S.A. | 617,834 | +305,236 |
| Goldman Sachs Group Inc | 556,927 | -18,214 |
Insiders
13 insiders reported holding 1,050,640 shares in total, about $25.7M at the last price.
| Holder | Shares |
|---|---|
| Karnani VikramPresident and CEO, Director | 197,864 |
| Tupper ColleenEVP & Chief Financial Officer | 147,282 |
| Santini GinoDirector | 112,483 |
| Smith Thomas BEVP and Chief Medical Officer | 90,651 |
| Freund John GordonDirector | 83,952 |
| Dieter DavidEVP & General Counsel | 77,071 |
| Dreyer ScottEVP & Chief Commercial Officer | 71,770 |
| Bohlin Garen GDirector | 71,000 |
| Fallon John A.Director | 64,634 |
| Balice-Gordon Rita J.Director | 61,370 |
Questions about COLL
What does Collegium Pharmaceutical, Inc do?
Collegium Pharmaceutical, Inc is a company in the Health care sector, listed on NASDAQ as COLL. Its shares trade on NASDAQ under the ticker COLL.
What is Collegium Pharmaceutical, Inc's net worth?
Collegium Pharmaceutical, Inc has a market value (market cap) of $796.6M at the latest share price, and shareholders' equity of $296.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Collegium Pharmaceutical, Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $38.2M on revenue of $815.2M, a net margin of 4.7%.
How much revenue does Collegium Pharmaceutical, Inc make?
Over the twelve months to September 30, 2026 Collegium Pharmaceutical, Inc reported revenue of $815.2M. That is 7.7% more than a year earlier.
When did Collegium Pharmaceutical, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Collegium Pharmaceutical, Inc's next earnings report?
Collegium Pharmaceutical, Inc's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare COLL with
Follow COLL
Get an email when Collegium Pharmaceutical, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Collegium Pharmaceutical, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.